Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 1
2003 6
2004 3
2005 5
2006 4
2007 3
2008 6
2009 4
2010 5
2011 10
2012 8
2013 5
2014 9
2015 10
2016 10
2017 12
2018 11
2019 4
2020 11
2021 11
2022 14
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis.
Cho MG, Kumar RJ, Lin CC, Boyer JA, Shahir JA, Fagan-Solis K, Simpson DA, Fan C, Foster CE, Goddard AM, Lerner LM, Ellington SW, Wang Q, Wang Y, Ho AY, Liu P, Perou CM, Zhang Q, McGinty RK, Purvis JE, Gupta GP. Cho MG, et al. Nature. 2024 Jan;625(7995):585-592. doi: 10.1038/s41586-023-06889-6. Epub 2024 Jan 10. Nature. 2024. PMID: 38200309 Free PMC article.
Here we report that the DNA double-strand break sensor MRE11 suppresses mammary tumorigenesis through a pivotal role in regulating cGAS activation. We demonstrate that binding of the MRE11-RAD50-NBN complex to nucleosome fragments is necessary to displace cGAS from acidic- …
Here we report that the DNA double-strand break sensor MRE11 suppresses mammary tumorigenesis through a pivotal role in regulating cGAS acti …
RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy.
Liu W, Zheng M, Zhang R, Jiang Q, Du G, Wu Y, Yang C, Li F, Li W, Wang L, Wu J, Shi L, Li W, Zhang K, Zhou Z, Liu R, Gao Y, Huang X, Fan S, Zhi X, Jiang D, Chen C. Liu W, et al. Adv Sci (Weinh). 2023 Feb;10(5):e2203884. doi: 10.1002/advs.202203884. Epub 2022 Dec 23. Adv Sci (Weinh). 2023. PMID: 36563124 Free PMC article.
Triple-negative breast cancer (TNBC) has higher molecular heterogeneity and metastatic potential and the poorest prognosis. ...Mechanistically, RNF126 physically associates with the MRE11-RAD50-NBS1 (MRN) complex and ubiquitinates MRE11 at K339 and K480 to increase …
Triple-negative breast cancer (TNBC) has higher molecular heterogeneity and metastatic potential and the poorest prognosis. ...Mechan …
The spectrum of genetic mutations in breast cancer.
Sheikh A, Hussain SA, Ghori Q, Naeem N, Fazil A, Giri S, Sathian B, Mainali P, Al Tamimi DM. Sheikh A, et al. Asian Pac J Cancer Prev. 2015;16(6):2177-85. doi: 10.7314/apjcp.2015.16.6.2177. Asian Pac J Cancer Prev. 2015. PMID: 25824734 Free article. Review.
Breast cancer is the most common malignancy in women around the world. ...However, the great majority of breast cancer cases are not related to a mutated gene of high penetrance, but to genes of low penetrance such as CHEK2, CDH1, NBS1, RAD50, BRIP1 and PALB2 …
Breast cancer is the most common malignancy in women around the world. ...However, the great majority of breast cancer cases a …
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.
Toh M, Ngeow J. Toh M, et al. Oncologist. 2021 Sep;26(9):e1526-e1537. doi: 10.1002/onco.13829. Epub 2021 Jun 2. Oncologist. 2021. PMID: 34021944 Free PMC article. Review.
Classically, BRCA1 and BRCA2 germline PVs are associated with significant breast and ovarian cancer risks. Patients with BRCA1 or BRCA2 PVs display worse clinical outcomes but respond better to platinum-based chemotherapies and poly-ADP ribose polymerase inhibitors, a trai …
Classically, BRCA1 and BRCA2 germline PVs are associated with significant breast and ovarian cancer risks. Patients with BRCA1 or BRC …
Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O, Baert-Desurmont S, Tinat J, Bera O, Dugast C, Berthet P, Polycarpe F, Layet V, Hardouin A, Frébourg T, Vaur D. Castéra L, et al. Eur J Hum Genet. 2014 Nov;22(11):1305-13. doi: 10.1038/ejhg.2014.16. Epub 2014 Feb 19. Eur J Hum Genet. 2014. PMID: 24549055 Free PMC article.
To optimize the molecular diagnosis of hereditary breast and ovarian cancer (HBOC), we developed a next-generation sequencing (NGS)-based screening based on the capture of a panel of genes involved, or suspected to be involved in HBOC, on pooling of indexed DNA and on pair …
To optimize the molecular diagnosis of hereditary breast and ovarian cancer (HBOC), we developed a next-generation sequencing (NGS)-b …
Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.
Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE, Lee SC. Chan GHJ, et al. Oncotarget. 2018 Jul 17;9(55):30649-30660. doi: 10.18632/oncotarget.25769. eCollection 2018 Jul 17. Oncotarget. 2018. PMID: 30093976 Free PMC article.
For patients with 2 primary cancers (n=205), the most common cancer pairs were bilateral breast (37.5%), breast-ovary (11.7%), endometrium-ovary (9.2%), colon-endometrium (3.9%) and colon-colon (3.4%). 42.3% patients underwent gene testing including 110/231 (47.6%) …
For patients with 2 primary cancers (n=205), the most common cancer pairs were bilateral breast (37.5%), breast-ovary (11.7%), …
RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors.
Ramos CRN, Oliveira RJS, Rosa MN, Pereira AS, de Abreu RBV, van Helvoort Lengert A, Reis RM, Silva VAO, Palmero EI, Melendez ME. Ramos CRN, et al. Curr Cancer Drug Targets. 2023;23(11):900-909. doi: 10.2174/1568009623666230418101511. Curr Cancer Drug Targets. 2023. PMID: 37076963
OBJECTIVE: The objective of this study is to evaluate whether RAD50 protein deficiency modulates the PARPi response in breast cancer cell lines. METHODS: T47D breast cancer cell line was modified using small interfering RNA and CRISPR/Cas9 technology, to knoc …
OBJECTIVE: The objective of this study is to evaluate whether RAD50 protein deficiency modulates the PARPi response in breast …
Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.
Chen X, Theobard R, Zhang J, Dai X. Chen X, et al. Biosci Rep. 2020 Jan 31;40(1):BSR20192546. doi: 10.1042/BSR20192546. Biosci Rep. 2020. PMID: 31872854 Free PMC article.
RAD50 is commonly depleted in basal-like breast cancer with concomitant absence of INPP4B and several tumor suppressors such as BRCA1 and TP53. Our previous study revealed that INPP4B and RAD50 interact and such an interaction is associated with breast …
RAD50 is commonly depleted in basal-like breast cancer with concomitant absence of INPP4B and several tumor suppressors such a …
Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients.
Karamat U, Ejaz S. Karamat U, et al. Curr Cancer Drug Targets. 2021;21(2):163-176. doi: 10.2174/1568009620666201009125507. Curr Cancer Drug Targets. 2021. PMID: 33038913 Review.
RESULTS: The promoter hyper-methylation and elevated expression of RAD50 was documented in various subgroups of breast invasive carcinoma. ...While RAD50 is overexpressed in breast cancer patients and thus makes tumor resistant against many anti-cancer …
RESULTS: The promoter hyper-methylation and elevated expression of RAD50 was documented in various subgroups of breast invasiv …
143 results